ASX 20

Sixteen major Australian & global research reports distilled into one tidy wire for your viewing pleasure!

...and why Seneca Financial Solutions' Ben Richards believes mining royalties could be a big opportunity in 2025.

Yesterday’s RBA meeting showed a marked dovish tilt in language, causing markets to reel in expectations for the first interest rate cut.

Livewire and Market Index readers cast their votes on the most promising stocks at the beginning of the year. Here's how they've performed.

Should you hold your bank shares? Should you sell them? Should you buy more, and if so, which ones? What do the charts say?

Bell Potter’s Grady Wulff tested audience requests and offered her own tips.

Marcus Today's Henry Jennings and Atlas Funds Management's Hugh Dive reflect on the year that was, and cast an eye towards 2025.

Should you hold your bank shares? Should you sell them? Should you buy more, and if so, which ones?

Using MarketMeter's research, we put three stock pickers to the test and asked them to highlight the highest-quality stocks on the ASX.

Plus, the only Big Bank in which this fund manager has an overweight position.

“The secret to wealth is finding the asymmetric payoff—small risk, big reward” Nassim Taleb Introduction When this writer first set about a career in finance we were...

Livewire recently hosted the inaugural MarketMeter insights lunch panels featuring some of the industry's most prominent fund managers.

We investigate ASX bank sector returns in 2024 to try to determine just how good they’ve been, and ponder what investors might get in 2025.

Australia has been a global leader in reducing smoking rates through stringent laws and health campaigns, but a new battlefront has emerged.

Investors can do a lot worse than picking quality growth stocks and staying the course. View from a personal experience

Time flies when you’re having fun! ASX stocks enter December, traditionally one of the strongest months of the year, in strong shape.

Metro and Arrow among the few ASX stocks offering leveraged exposure; Plus, Spartan and Rumble take the week’s gold honours.

This $60m ASX-listed biotech, with a cutting-edge pipeline of transformative therapies, stands at a key inflection point for value creation.

Our guest for this Ep is Jennifer Westacott AO & what a conversation it is – an inspiring story of one of Australia’s leading women.

High quality companies have been repeat M&A targets of late. This wire details the material demand for high quality assets across sectors

You'll find out in this episode of Buy Hold Sell.

With the S&P/ASX 200 hitting new highs, we ask “What’s in store for 2025?” How much higher can Aussie shares go!?

Plus, why investors will have to question whether Donald Trump's pro-growth policies are really pro-inflation ones.

Its model portfolio may have underperformed the benchmark by 2.25%, but Morgan Stanley's sell-side team are holding firm to their call.